Natalia Redondo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Natalia Redondo has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
Esther González
Department of Nephrology, Hospital Universitario “12 de Octubre”, Instituto de Investigación Sanitaria Hospital “12 de Octubre” (imas12), Madrid, Spain
11 shared publications- José María Aguado
Unit of Infectious Diseases Hospital Universitario “12 de Octubre” Instituto de Investigación Sanitaria Hospital “12 de Octubre” (imas12) Madrid Spain
11 shared publications - Mario Fernández-Ruiz
Unit of Infectious Diseases, Hospital Universitario “12 de Octubre”, Instituto de Investigación Sanitaria Hospital “12 de Octubre” (imas12), Madrid, Spain
11 shared publications - Francisco López-Medrano
Unit of Infectious Diseases, University Hospital ‘12 de Octubre’, Madrid, Spain
10 shared publications - Luis Carrasco
Centro de Biología Molecular “Severo Ochoa” (CSIC-UAM), Universidad Autónoma de Madrid, Madrid, Spain
10 shared publications - Rafael San Juan
Unit of Infectious Diseases Hospital Universitario “12 de Octubre” Instituto de Investigación Sanitaria Hospital “12 de Octubre” (imas12) Madrid Spain
10 shared publications
Latest Publications
- Open Access
- 21 May 2025
- Published by Frontiers Media SA in Transplant International
- Vol. 38, 14648
CTLA4 Single-Nucleotide Polymorphisms Influence the Risk of HSV and VZV Infection in Kidney Transplant Recipients: A Prospective Cohort Study
Herpesviruses are able to modulate adaptive T-cell-mediated responses to establish latency within the host. Reactivation of herpes simplex virus (HSV)-1/2 and varicella zoster virus (VZV) is a frequent and potentially serious complication among kidney transplant recipients (KTRs). The ability of clinical criteria to identify KTRs at increased risk of α-herpesvirus (HSV/VZV) infection is limited. We investigated the effect of two single nucleotide polymorphisms (SNPs) in the cytotoxic T-lymphocyte antigen 4 (CTLA4) gene in a single-center cohort of 204 KTRs. After a median follow-up of 3.1 years, 34 of them (16.7%) experienced 22 episodes of zoster and 15 episodes of HSV-1/2 infection. Homozygous carriers of the minor allele of rs231775 had a higher cumulative incidence of α-herpesvirus infection (23.5% for GG versus 7.6% for AA/AG carriers; P-value = 0.011) and a lower infection-free survival (log-rank P-value = 0.037). After multivariable adjustment by clinical factors (including use of valganciclovir prophylaxis and acute rejection as time-dependent variables), the GG genotype of CTLA4 (rs231775) SNP was associated to the study outcome (adjusted hazard ratio: 3.21; 95% confidence interval: 1.44–7.16). In conclusion, genetic polymorphisms in the co-inhibitory T-cell receptor CTLA-4 may be detrimental for the immune control of latent HSV/VZV infection in KTRs.
- 21 May 2025
- Published by Frontiers Media SA in Transplant International
- Vol. 38, 14648
Open AccessCTLA4 Single-Nucleotide Polymorphisms Influence the Risk of HSV and VZV Infection in Kidney Transplant Recipients: A Prospective Cohort Study
Herpesviruses are able to modulate adaptive T-cell-mediated responses to establish latency within the host. Reactivation of herpes simplex virus (HSV)-1/2 and varicella zoster virus (VZV) is a frequent and potentially serious complication among kidney transplant recipients (KTRs). The ability of clinical criteria to identify KTRs at increased risk of α-herpesvirus (HSV/VZV) infection is limited. We investigated the effect of two single nucleotide polymorphisms (SNPs) in the cytotoxic T-lymphocyte antigen 4 (CTLA4) gene in a single-center cohort of 204 KTRs. After a median follow-up of 3.1 years, 34 of them (16.7%) experienced 22 episodes of zoster and 15 episodes of HSV-1/2 infection. Homozygous carriers of the minor allele of rs231775 had a higher cumulative incidence of α-herpesvirus infection (23.5% for GG versus 7.6% for AA/AG carriers; P-value = 0.011) and a lower infection-free survival (log-rank P-value = 0.037). After multivariable adjustment by clinical factors (including use of valganciclovir prophylaxis and acute rejection as time-dependent variables), the GG genotype of CTLA4 (rs231775) SNP was associated to the study outcome (adjusted hazard ratio: 3.21; 95% confidence interval: 1.44–7.16). In conclusion, genetic polymorphisms in the co-inhibitory T-cell receptor CTLA-4 may be detrimental for the immune control of latent HSV/VZV infection in KTRs.
- Open Access
- 26 April 2025
- Published by Wiley in Transplant Infectious Disease
- Vol. 27 (4) , e70038
Knowledge and Adherence to Lifestyle Habits to Prevent Complications Associated With Immunosuppression in Kidney Transplant Recipients: A Single‐Center Survey
Background: Chronic immunosuppression associated with certain lifestyle habits render kidney transplant (KT) recipients more susceptible to infection and cancer. We assessed the level of knowledge and adherence to safe living strategies to minimize the occurrence of posttransplant complications. Methods: Consecutive KT recipients were offered a self‐administered questionnaire covering the following areas: demographics and socioeconomic factors; generic hygiene habits; sun exposure; smoking and alcohol consumption; vaccination status; animal contact and gardening; international travelling; and food safety and habits. Results: Between May 2019 and May 2021, 130 KT recipients responded the survey at a median of 61.5 posttransplant days (completion rate of 94.9%). Only 19.7% of participants visited the dentist at least every 3–6 months. Although the majority (88.5%) were aware of the need of sunscreen, only 23.3% used it throughout the year. Self‐reported influenza vaccine uptake in the last session was 69.1%. Pet ownership was reported by 41.7% of participants, of which more than one‐third had considered to give up the care of their animals. Gardening and international travel were uncommon. A notable proportion of participants acknowledged to consume the following products either “usually” or “often”: raw or undercooked meat (12.4%), undercooked fish (24.8%), raw seafood (8.8%), homemade sausages or cured ham (51.5%), pâté or meat spreads (35.2%), and “ready‐to‐eat” salads (31.8%). Adherence was poorer among non‐native‐speaking patients and those with lower education and household incomes. Conclusion: There is room for improvement in health education and promotion practices among KT recipients, particularly those with potential cultural and socioeconomic barriers.
- 26 April 2025
- Published by Wiley in Transplant Infectious Disease
- Vol. 27 (4) , e70038
Open AccessKnowledge and Adherence to Lifestyle Habits to Prevent Complications Associated With Immunosuppression in Kidney Transplant Recipients: A Single‐Center Survey
Background: Chronic immunosuppression associated with certain lifestyle habits render kidney transplant (KT) recipients more susceptible to infection and cancer. We assessed the level of knowledge and adherence to safe living strategies to minimize the occurrence of posttransplant complications. Methods: Consecutive KT recipients were offered a self‐administered questionnaire covering the following areas: demographics and socioeconomic factors; generic hygiene habits; sun exposure; smoking and alcohol consumption; vaccination status; animal contact and gardening; international travelling; and food safety and habits. Results: Between May 2019 and May 2021, 130 KT recipients responded the survey at a median of 61.5 posttransplant days (completion rate of 94.9%). Only 19.7% of participants visited the dentist at least every 3–6 months. Although the majority (88.5%) were aware of the need of sunscreen, only 23.3% used it throughout the year. Self‐reported influenza vaccine uptake in the last session was 69.1%. Pet ownership was reported by 41.7% of participants, of which more than one‐third had considered to give up the care of their animals. Gardening and international travel were uncommon. A notable proportion of participants acknowledged to consume the following products either “usually” or “often”: raw or undercooked meat (12.4%), undercooked fish (24.8%), raw seafood (8.8%), homemade sausages or cured ham (51.5%), pâté or meat spreads (35.2%), and “ready‐to‐eat” salads (31.8%). Adherence was poorer among non‐native‐speaking patients and those with lower education and household incomes. Conclusion: There is room for improvement in health education and promotion practices among KT recipients, particularly those with potential cultural and socioeconomic barriers.
- 20 January 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (1) , e70178
Human Cytomegalovirus Infection Induces Long‐Term Changes in the Cytokine Milieu of Kidney Transplant Recipients
The impact of human cytomegalovirus (HCMV) infection on the mid‐ and long‐term balance between pro‐inflammatory and anti‐inflammatory cytokines among kidney transplant recipients (KTRs) remains unclear. We measured plasma levels of 12 Th1/Th2‐type cytokines (granulocyte‐macrophage colony‐stimulating factor, interferon‐γ, interleukin [IL]‐1β, IL‐2, IL‐4, IL‐5, IL‐6, IL‐10, IL‐12p70, IL‐13, IL‐18 and tumor necrosis factor‐α) in a cohort of 290 KTRs at four time points through month 12 after transplantation. Cytokine levels at each point were compared according to the previous documentation of HCMV replication by two approaches: “cumulative exposure” from the time of transplantation and “recent exposure” within the 2–3 months preceding cytokine assessment. Significance levels were Bonferroni‐corrected for multiple pairwise comparisons. Plasma levels of IL‐6, IL‐10, and IL‐12p70 at month 1 were significantly increased in KTRs that had experienced HCMV infection during the first 30 days. By month 3, IL‐6 and IL‐10 remained increased in KTRs with cumulative exposure through day 90. Cumulative exposure to HCMV replication through day 180 was also associated to increased IL‐10 levels at month 6. In addition, KTRs with recent HCMV exposure had increased IL‐10 levels at months 3 and 6. After multivariable adjustment, cumulative exposure to HCMV infection and/or the area under curve of HCMV DNAemia during the corresponding period were associated to IL‐10 levels within the highest quartile at months 1, 3, and 6. Preceding HCMV infection induces sustained changes in the plasma cytokine milieu of KTRs, with elevated IL‐6 and IL‐10 levels throughout the first 6 months after transplantation.
- 20 January 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (1) , e70178
Human Cytomegalovirus Infection Induces Long‐Term Changes in the Cytokine Milieu of Kidney Transplant Recipients
The impact of human cytomegalovirus (HCMV) infection on the mid‐ and long‐term balance between pro‐inflammatory and anti‐inflammatory cytokines among kidney transplant recipients (KTRs) remains unclear. We measured plasma levels of 12 Th1/Th2‐type cytokines (granulocyte‐macrophage colony‐stimulating factor, interferon‐γ, interleukin [IL]‐1β, IL‐2, IL‐4, IL‐5, IL‐6, IL‐10, IL‐12p70, IL‐13, IL‐18 and tumor necrosis factor‐α) in a cohort of 290 KTRs at four time points through month 12 after transplantation. Cytokine levels at each point were compared according to the previous documentation of HCMV replication by two approaches: “cumulative exposure” from the time of transplantation and “recent exposure” within the 2–3 months preceding cytokine assessment. Significance levels were Bonferroni‐corrected for multiple pairwise comparisons. Plasma levels of IL‐6, IL‐10, and IL‐12p70 at month 1 were significantly increased in KTRs that had experienced HCMV infection during the first 30 days. By month 3, IL‐6 and IL‐10 remained increased in KTRs with cumulative exposure through day 90. Cumulative exposure to HCMV replication through day 180 was also associated to increased IL‐10 levels at month 6. In addition, KTRs with recent HCMV exposure had increased IL‐10 levels at months 3 and 6. After multivariable adjustment, cumulative exposure to HCMV infection and/or the area under curve of HCMV DNAemia during the corresponding period were associated to IL‐10 levels within the highest quartile at months 1, 3, and 6. Preceding HCMV infection induces sustained changes in the plasma cytokine milieu of KTRs, with elevated IL‐6 and IL‐10 levels throughout the first 6 months after transplantation.
- 10 January 2025
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (1) , e14437
Diagnostic Performance of Two Different Techniques to Quantify CMV‐Specific Cell‐Mediated Immunity in Intermediate‐Risk Seropositive Kidney Transplant Recipients
Background: Kidney transplant (KT) recipients at intermediate risk for cytomegalovirus (CMV) infection constitute a potential target for individualized prevention strategies informed by the CMV‐specific cell‐mediated immunity (CMV‐CMI). The optimal method for the functional assessment of CMV‐CMI in this group remains unclear. Methods: We included 74 CMV‐seropositive KT recipients that did not receive T‐cell‐depleting induction and were managed by preemptive therapy. CMV‐CMI was monitored at baseline and months 1, 3, 6, and 12 by intracellular cytokine staining (ICS) and a interferon (IFN)‐γ‐release assay (QuantiFERON‐CMV [QTF‐CMV]). Both methods were compared for discriminative capacity (areas under the receiving operating characteristic curve [auROCs]) and diagnostic accuracy to predict protection against high‐level (≥1000 IU/mL) CMV DNAemia and/or disease. Results: Eighteen patients (24.3%) experienced high‐level CMV DNAemia or disease. There were no significant differences in the discriminative capacity to predict protection of CMV‐specific CD8+ (auROC: 0.719) and CD4+ T‐cell counts (auROC: 0.664) enumerated by ICS and IFN‐γ production measured by QTF‐CMV (auROC: 0.666). Optimal cutoff values of ≥9.8 CMV‐specific CD4+ T‐cells/µL and ≥5.7 CD8+ T‐cells/µL by ICS yielded excellent specificity (95.7% and 86.9%, respectively) and positive predictive values (PPVs) (>98.0%), but a sensitivity below 60%. A reactive QTF‐CMV (IFN‐γ ≥0.2 IU/mL) provided good sensitivity (81.6%) and PPV (92.5%), at the expense of a poor specificity (22.2%). Conclusions: The discriminative capacity to predict immune protection against clinically relevant CMV infection among intermediate‐risk KT recipients was comparable for ICS and QTF‐CMV. A selected ICS threshold may provide better specificity than the interpretative cut‐off values currently recommended for QTF‐CMV. image
- 10 January 2025
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (1) , e14437
Diagnostic Performance of Two Different Techniques to Quantify CMV‐Specific Cell‐Mediated Immunity in Intermediate‐Risk Seropositive Kidney Transplant Recipients
Background: Kidney transplant (KT) recipients at intermediate risk for cytomegalovirus (CMV) infection constitute a potential target for individualized prevention strategies informed by the CMV‐specific cell‐mediated immunity (CMV‐CMI). The optimal method for the functional assessment of CMV‐CMI in this group remains unclear. Methods: We included 74 CMV‐seropositive KT recipients that did not receive T‐cell‐depleting induction and were managed by preemptive therapy. CMV‐CMI was monitored at baseline and months 1, 3, 6, and 12 by intracellular cytokine staining (ICS) and a interferon (IFN)‐γ‐release assay (QuantiFERON‐CMV [QTF‐CMV]). Both methods were compared for discriminative capacity (areas under the receiving operating characteristic curve [auROCs]) and diagnostic accuracy to predict protection against high‐level (≥1000 IU/mL) CMV DNAemia and/or disease. Results: Eighteen patients (24.3%) experienced high‐level CMV DNAemia or disease. There were no significant differences in the discriminative capacity to predict protection of CMV‐specific CD8+ (auROC: 0.719) and CD4+ T‐cell counts (auROC: 0.664) enumerated by ICS and IFN‐γ production measured by QTF‐CMV (auROC: 0.666). Optimal cutoff values of ≥9.8 CMV‐specific CD4+ T‐cells/µL and ≥5.7 CD8+ T‐cells/µL by ICS yielded excellent specificity (95.7% and 86.9%, respectively) and positive predictive values (PPVs) (>98.0%), but a sensitivity below 60%. A reactive QTF‐CMV (IFN‐γ ≥0.2 IU/mL) provided good sensitivity (81.6%) and PPV (92.5%), at the expense of a poor specificity (22.2%). Conclusions: The discriminative capacity to predict immune protection against clinically relevant CMV infection among intermediate‐risk KT recipients was comparable for ICS and QTF‐CMV. A selected ICS threshold may provide better specificity than the interpretative cut‐off values currently recommended for QTF‐CMV. image
- Open Access
- 2 February 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (7) , 1180-1192
Human microRNA sequencing and cytomegalovirus infection risk after kidney transplantation
- 2 February 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (7) , 1180-1192
Open AccessHuman microRNA sequencing and cytomegalovirus infection risk after kidney transplantation
- 11 December 2023
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 43 (2) , 313-324
Predictive value of fecal calprotectin and lactoferrin levels for negative outcomes in Clostridioides difficile infection
Purpose We investigated the role of fecal calprotectin (FC) and lactoferrin (FL) as predictive biomarkers in Clostridioides difficile infection (CDI). Methods We assembled a prospective cohort including all patients with a laboratory-confirmed CDI diagnosis between January and December 2017. FL and FC levels were measured at diagnosis by commercial ELISA and EIA kits. We investigated the diagnostic accuracy of FC and FL to predict CDI recurrence and severity (study outcomes) and explored optimal cut-off values in addition to those proposed by the manufacturers (200 µg/g and 7.2 µg/mL, respectively). Results We included 170 CDI cases (152 first episodes and 18 recurrences). The rates of recurrence (first episodes only) and severity (entire cohort) were 9.2% (14/152) and 46.5% (79/170). Both FL and FC levels were significantly higher in patients who developed study outcomes. Optimal cut-off values for FC and FL to predict CDI recurrence were 1052 µg/g and 6.0 µg/mL. The optimal cut-off value for FC yielded higher specificity (60.9%) and positive predictive value (PPV) (16.9%) than that proposed by the manufacturer. Regarding CDI severity, the optimal cut-off value for FC (439 µg/g) also provided higher specificity (43.9%) and PPV (54.1%) than that of the manufacturer, whereas the optimal cut-off value for FL (4.6 µg/mL) resulted in an improvement of PPV (57.5%). Conclusion By modifying the thresholds for assay positivity, the measurement of FC and FL at diagnosis is useful to predict recurrence and severity in CDI. Adding these biomarkers to current clinical scores may help to individualize CDI management.
- 11 December 2023
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 43 (2) , 313-324
Predictive value of fecal calprotectin and lactoferrin levels for negative outcomes in Clostridioides difficile infection
Purpose We investigated the role of fecal calprotectin (FC) and lactoferrin (FL) as predictive biomarkers in Clostridioides difficile infection (CDI). Methods We assembled a prospective cohort including all patients with a laboratory-confirmed CDI diagnosis between January and December 2017. FL and FC levels were measured at diagnosis by commercial ELISA and EIA kits. We investigated the diagnostic accuracy of FC and FL to predict CDI recurrence and severity (study outcomes) and explored optimal cut-off values in addition to those proposed by the manufacturers (200 µg/g and 7.2 µg/mL, respectively). Results We included 170 CDI cases (152 first episodes and 18 recurrences). The rates of recurrence (first episodes only) and severity (entire cohort) were 9.2% (14/152) and 46.5% (79/170). Both FL and FC levels were significantly higher in patients who developed study outcomes. Optimal cut-off values for FC and FL to predict CDI recurrence were 1052 µg/g and 6.0 µg/mL. The optimal cut-off value for FC yielded higher specificity (60.9%) and positive predictive value (PPV) (16.9%) than that proposed by the manufacturer. Regarding CDI severity, the optimal cut-off value for FC (439 µg/g) also provided higher specificity (43.9%) and PPV (54.1%) than that of the manufacturer, whereas the optimal cut-off value for FL (4.6 µg/mL) resulted in an improvement of PPV (57.5%). Conclusion By modifying the thresholds for assay positivity, the measurement of FC and FL at diagnosis is useful to predict recurrence and severity in CDI. Adding these biomarkers to current clinical scores may help to individualize CDI management.
- 22 September 2023
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 229 (6) , 1812-1816
Dynamics and Clinical Significance of Cytomegalovirus-Specific Neutralizing Antibodies in Kidney Transplant Recipients Treated with T-Cell–Depleting Agents
We measured cytomegalovirus (CMV)-specific antibodies that neutralize epithelial cell infection (CMV-AbNEIs) in 101 CMV-seropositive kidney transplant recipients (KTRs) at baseline and posttransplant months 3 and 6. All the patients received antithymocyte globulin and 3-month valganciclovir prophylaxis. There were no significant differences in pretransplant AbNEIs titers between KTRs that developed or did not develop any-level CMV infection or the composite of high-level infection and/or disease. One-year CMV infection-free survival was comparable between KTRs with or without pretransplant CMV-AbNEIs. No differences were observed by months 3 and 6. We observed no protective role for CMV-AbNEIs among CMV-seropositive KTRs undergoing T-cell–depleting induction.
- 22 September 2023
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 229 (6) , 1812-1816
Dynamics and Clinical Significance of Cytomegalovirus-Specific Neutralizing Antibodies in Kidney Transplant Recipients Treated with T-Cell–Depleting Agents
We measured cytomegalovirus (CMV)-specific antibodies that neutralize epithelial cell infection (CMV-AbNEIs) in 101 CMV-seropositive kidney transplant recipients (KTRs) at baseline and posttransplant months 3 and 6. All the patients received antithymocyte globulin and 3-month valganciclovir prophylaxis. There were no significant differences in pretransplant AbNEIs titers between KTRs that developed or did not develop any-level CMV infection or the composite of high-level infection and/or disease. One-year CMV infection-free survival was comparable between KTRs with or without pretransplant CMV-AbNEIs. No differences were observed by months 3 and 6. We observed no protective role for CMV-AbNEIs among CMV-seropositive KTRs undergoing T-cell–depleting induction.
- Open Access
- 20 September 2023
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 9 (10) , e1536
Cell-mediated and Neutralizing Antibody Responses to the SARS-CoV-2 Omicron BA.4/BA.5–adapted Bivalent Vaccine Booster in Kidney and Liver Transplant Recipients
Background.: The immunogenicity elicited by the Omicron BA.4/BA.5–adapted bivalent booster vaccine after solid organ transplantation (SOT) has not been characterized. Methods.: We assessed cell-mediated and neutralizing IgG antibody responses against the BA.4/BA.5 spike receptor-binding domain at baseline and 2 wk after the administration of an mRNA-based bivalent (ancestral strain and BA.4/BA.5 subvariants) vaccine among 30 SOT recipients who had received ≥3 monovalent vaccine doses. Previous coronavirus disease 2019 history was present in 46.7% of them. We also recruited a control group of 19 nontransplant healthy individuals. Cell-mediated immunity was measured by fluorescent ELISpot assay for interferon (IFN)-γ secretion, whereas the neutralizing IgG antibody response against the BA.4/BA.5 spike receptor-binding domain was quantified with a competitive ELISA. Results.: The median number of BA.4/BA.5 spike–specific IFN-γ–producing spot-forming units (SFUs) increased from baseline to 2 wk postbooster (83.8 versus 133.0 SFUs/106 peripheral blood mononuclear cells; P = 0.0017). Seropositivity rate also increased (46.7%–83.3%; P = 0.001), as well as serum neutralizing activity (4.2%–78.3%; P < 0.0001). Patients with no prior coronavirus disease 2019 history experienced higher improvements in cell-mediated and neutralizing responses after booster vaccination. There was no correlation between BA.4/BA.5 spike–specific IFN-γ–producing SFUs and neutralizing activity. Nontransplant controls showed more robust postbooster cell-mediated immunity than SOT recipients (591.1 versus 133.0 IFN-γ–producing SFUs/106 peripheral blood mononuclear cells; P < 0.0001), although no differences were observed for antibody responses in terms of postbooster seropositivity rates or neutralizing activity. Conclusions.: Booster with the BA.4/BA.5–adapted bivalent vaccine generated strong subvariant-specific responses among SOT recipients. Booster-induced cell-mediated immunity, however, remained lower than in immunocompetent individuals.
- 20 September 2023
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 9 (10) , e1536
Open AccessCell-mediated and Neutralizing Antibody Responses to the SARS-CoV-2 Omicron BA.4/BA.5–adapted Bivalent Vaccine Booster in Kidney and Liver Transplant Recipients
Background.: The immunogenicity elicited by the Omicron BA.4/BA.5–adapted bivalent booster vaccine after solid organ transplantation (SOT) has not been characterized. Methods.: We assessed cell-mediated and neutralizing IgG antibody responses against the BA.4/BA.5 spike receptor-binding domain at baseline and 2 wk after the administration of an mRNA-based bivalent (ancestral strain and BA.4/BA.5 subvariants) vaccine among 30 SOT recipients who had received ≥3 monovalent vaccine doses. Previous coronavirus disease 2019 history was present in 46.7% of them. We also recruited a control group of 19 nontransplant healthy individuals. Cell-mediated immunity was measured by fluorescent ELISpot assay for interferon (IFN)-γ secretion, whereas the neutralizing IgG antibody response against the BA.4/BA.5 spike receptor-binding domain was quantified with a competitive ELISA. Results.: The median number of BA.4/BA.5 spike–specific IFN-γ–producing spot-forming units (SFUs) increased from baseline to 2 wk postbooster (83.8 versus 133.0 SFUs/106 peripheral blood mononuclear cells; P = 0.0017). Seropositivity rate also increased (46.7%–83.3%; P = 0.001), as well as serum neutralizing activity (4.2%–78.3%; P < 0.0001). Patients with no prior coronavirus disease 2019 history experienced higher improvements in cell-mediated and neutralizing responses after booster vaccination. There was no correlation between BA.4/BA.5 spike–specific IFN-γ–producing SFUs and neutralizing activity. Nontransplant controls showed more robust postbooster cell-mediated immunity than SOT recipients (591.1 versus 133.0 IFN-γ–producing SFUs/106 peripheral blood mononuclear cells; P < 0.0001), although no differences were observed for antibody responses in terms of postbooster seropositivity rates or neutralizing activity. Conclusions.: Booster with the BA.4/BA.5–adapted bivalent vaccine generated strong subvariant-specific responses among SOT recipients. Booster-induced cell-mediated immunity, however, remained lower than in immunocompetent individuals.
- 21 August 2023
- Published by Wiley in Transplant Infectious Disease
- Vol. 25 (5) , e14132
Previous use of statins does not improve the outcome of bloodstream infection after kidney transplantation
Previous studies have suggested that exposure to statins confers a protective effect in bloodstream infection (BSI) due to the anti‐inflammatory and immunomodulatory properties attributed to these lipid‐lowering drugs. Scarce evidence is available for the solid organ transplant population. Therefore, we compared the time to clinical cure (primary outcome) and the time to fever resolution, new requirement of intensive care unit admission or renal replacement therapy, and 30‐day all‐cause mortality (secondary outcomes) between kidney transplant (KT) recipients with post‐transplant BSI that were receiving or not statin therapy for at least the previous 30 days. We included 80 KT recipients that developed 109 BSI episodes (43 [39.4%] and 66 [60.6%] episodes within the statin and non‐statin groups, respectively). The median interval since the initial prescription to BSI was 512 days (interquartile range [IQR]: 172–1388). Most episodes were of urinary source and due to Enterobacterales. There were no differences in the median time to clinical cure in the statin and non‐statin groups (3.4 [IQR: 3–6.8] versus 4 [IQR: 2–6] days; p‐value = .112). The lack of effect was confirmed by multiple linear regression analysis adjusted for confounding factors (standardized β coefficient = 0.040; p‐value = .709). No significant differences were observed for any of the secondary outcomes either. Vital signs and laboratory values at BSI onset and after 72–96 h were similar in both groups. In conclusion, previous statin therapy had no apparent protective effect on the outcome of post‐transplant BSI among KT recipients. image
- 21 August 2023
- Published by Wiley in Transplant Infectious Disease
- Vol. 25 (5) , e14132
Previous use of statins does not improve the outcome of bloodstream infection after kidney transplantation
Previous studies have suggested that exposure to statins confers a protective effect in bloodstream infection (BSI) due to the anti‐inflammatory and immunomodulatory properties attributed to these lipid‐lowering drugs. Scarce evidence is available for the solid organ transplant population. Therefore, we compared the time to clinical cure (primary outcome) and the time to fever resolution, new requirement of intensive care unit admission or renal replacement therapy, and 30‐day all‐cause mortality (secondary outcomes) between kidney transplant (KT) recipients with post‐transplant BSI that were receiving or not statin therapy for at least the previous 30 days. We included 80 KT recipients that developed 109 BSI episodes (43 [39.4%] and 66 [60.6%] episodes within the statin and non‐statin groups, respectively). The median interval since the initial prescription to BSI was 512 days (interquartile range [IQR]: 172–1388). Most episodes were of urinary source and due to Enterobacterales. There were no differences in the median time to clinical cure in the statin and non‐statin groups (3.4 [IQR: 3–6.8] versus 4 [IQR: 2–6] days; p‐value = .112). The lack of effect was confirmed by multiple linear regression analysis adjusted for confounding factors (standardized β coefficient = 0.040; p‐value = .709). No significant differences were observed for any of the secondary outcomes either. Vital signs and laboratory values at BSI onset and after 72–96 h were similar in both groups. In conclusion, previous statin therapy had no apparent protective effect on the outcome of post‐transplant BSI among KT recipients. image
- Open Access
- 13 April 2023
- Published by Wiley in Journal of Medical Virology
- Vol. 95 (4) , e28733
Comparison of intracellular cytokine staining versus an ELISA‐based assay to assess CMV‐specific cell‐mediated immunity in high‐risk kidney transplant recipients
The best method for monitoring cytomegalovirus (CMV)‐specific cell‐mediated immunity (CMV‐CMI) among high‐risk kidney transplant (KT) recipients remains uncertain. We assessed CMV‐CMI by intracellular cytokine staining (ICS) by flow cytometry and a commercial interferon (IFN)‐γ release assay (QuantiFERON®‐CMV [QTF‐CMV]) at posttransplant months 3, 4, and 5 in 53 CMV‐seropositive KT recipients that had received induction therapy with antithymocyte globulin (ATG) and a 3‐month course of valganciclovir prophylaxis. The discriminative capacity (areas under receiver operating characteristics curve [auROCs]) and diagnostic accuracy to predict immune protection against CMV infection from the discontinuation of prophylaxis to month 12 were compared between both methods. There was significant although moderate correlations between CMV‐specific IFN‐γ‐producing CD8+ T‐cell counts enumerated by ICS and IFN‐γ levels by QTF‐CMV at months 3 (rho: 0.493; p = 0.005) and 4 (rho: 0.440; p = 0.077). The auROCs for CMV‐specific CD4+ and CD8+ T‐cells by ICS were nonsignificantly higher than that of QTF‐CMV (0.696 and 0.733 vs. 0.678; p = 0.900 and 0.692, respectively). The optimal cut‐off of ≥0.395 CMV‐specific CD8+ T‐cells yielded a sensitivity of 86.4%, specificity of 54.6%, positive predictive value of 79.2% and negative predictive value of 66.7% to predict protection. The corresponding estimates for QTF‐CMV (IFN‐γ levels ≥0.2 IU/mL) were 78.9%, 37.5%, 75.0%, and 42.9%, respectively. The enumeration of CMV‐specific IFN‐γ‐producing CD8+ T‐cells at the time of cessation of prophylaxis performed slightly better than the QTF‐CMV assay to predict immune protection in seropositive KT recipients previously treated with ATG.
- 13 April 2023
- Published by Wiley in Journal of Medical Virology
- Vol. 95 (4) , e28733
Open AccessComparison of intracellular cytokine staining versus an ELISA‐based assay to assess CMV‐specific cell‐mediated immunity in high‐risk kidney transplant recipients
The best method for monitoring cytomegalovirus (CMV)‐specific cell‐mediated immunity (CMV‐CMI) among high‐risk kidney transplant (KT) recipients remains uncertain. We assessed CMV‐CMI by intracellular cytokine staining (ICS) by flow cytometry and a commercial interferon (IFN)‐γ release assay (QuantiFERON®‐CMV [QTF‐CMV]) at posttransplant months 3, 4, and 5 in 53 CMV‐seropositive KT recipients that had received induction therapy with antithymocyte globulin (ATG) and a 3‐month course of valganciclovir prophylaxis. The discriminative capacity (areas under receiver operating characteristics curve [auROCs]) and diagnostic accuracy to predict immune protection against CMV infection from the discontinuation of prophylaxis to month 12 were compared between both methods. There was significant although moderate correlations between CMV‐specific IFN‐γ‐producing CD8+ T‐cell counts enumerated by ICS and IFN‐γ levels by QTF‐CMV at months 3 (rho: 0.493; p = 0.005) and 4 (rho: 0.440; p = 0.077). The auROCs for CMV‐specific CD4+ and CD8+ T‐cells by ICS were nonsignificantly higher than that of QTF‐CMV (0.696 and 0.733 vs. 0.678; p = 0.900 and 0.692, respectively). The optimal cut‐off of ≥0.395 CMV‐specific CD8+ T‐cells yielded a sensitivity of 86.4%, specificity of 54.6%, positive predictive value of 79.2% and negative predictive value of 66.7% to predict protection. The corresponding estimates for QTF‐CMV (IFN‐γ levels ≥0.2 IU/mL) were 78.9%, 37.5%, 75.0%, and 42.9%, respectively. The enumeration of CMV‐specific IFN‐γ‐producing CD8+ T‐cells at the time of cessation of prophylaxis performed slightly better than the QTF‐CMV assay to predict immune protection in seropositive KT recipients previously treated with ATG.